Skip to main content
Margrit Wiesendanger, MD, Rheumatology, New York, NY

MargritWiesendangerMDPhD

Rheumatology • New York, NY

Lupus & Related, Rheumatoid Arthritis & Related, Spondyloarthropathy

Associate Professor of Medicine and Program Director, Division of Rheumatology, Icahn School of Medicine at Mount Sinai

Join to view full profile

Dr. Wiesendanger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wiesendanger's full profile

Already have an account?

  • Office

    5 E 98th St
    New York, NY 10029
    Phone+1 212-241-1671
    Fax+1 212-241-3243

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Rheumatology, 2005 - 2008
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2003
  • Albert Einstein College of Medicine
    Albert Einstein College of MedicineClass of 2000

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2001 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Fellow American College of Physicians, 2011
  • Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2013-2016
  • Fellow American College of Rheumatology

Publications & Presentations

PubMed

Press Mentions

  • FDA Gives Thumbs up to ANCA-Associated Vasculitis Drug
    FDA Gives Thumbs up to ANCA-Associated Vasculitis DrugOctober 8th, 2021
  • FDA Advisors Split on New Drug for Vasculitis
    FDA Advisors Split on New Drug for VasculitisMay 7th, 2021
  • Adcomm Splits Slightly in Favor of FDA Approving ChemoCentryx’s Rare Disease Drug
    Adcomm Splits Slightly in Favor of FDA Approving ChemoCentryx’s Rare Disease DrugMay 6th, 2021

Committees

  • Physician IT Liaison, Ambulatory Care Network Quality and Patient Safety Committee 2014 - 2015

Professional Memberships

Other Languages

  • Spanish, French

Dr. Margrit Wiesendanger, Dr. Margrit Wiesendanger, MD, Dr. M Wiesendanger